Biomarker Guided Treatment in Gynaecological Cancer (Momatec2)
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series.
Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers.
Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.
調査の概要
状態
条件
研究の種類
入学 (予想される)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Jone Trovik, MD PhD Prof
- 電話番号:+4755974200
- メール:jone.trovik@k2.uib.no
研究連絡先のバックアップ
- 名前:Henrica MJ Werner, MD PhD MRCOG
- 電話番号:+4755974200
- メール:henrica.werner@k2.uib.no
研究場所
-
-
-
Nijmegen、オランダ
- まだ募集していません
- Radboud University Hospital
-
コンタクト:
- Hanny MA Pijnenborg, MD, PhD
-
コンタクト:
- Casper Reijne, MD
-
-
-
-
-
Alesund、ノルウェー、6017
- 募集
- Ålesund Hospital
-
コンタクト:
- Margaret S Lode, MD
-
Førde、ノルウェー、6812
- 募集
- Førde Central Hospital
-
コンタクト:
- Jostein Tjugum, MD
-
コンタクト:
- marthe LT Larsson, MD
-
Kristiansand、ノルウェー、4604
- まだ募集していません
- Sørlandet hospital
-
コンタクト:
- Ane C Munk, MD, PhD
-
コンタクト:
- ingvild Vistad, MD, PhD
-
Oslo、ノルウェー
- 募集
- Akershus University Hospital
-
コンタクト:
- marie E Engh, MD
-
Stavanger、ノルウェー、4011
- 募集
- Stavanger University Hospital
-
コンタクト:
- Elisabeth B Nilsen, MD
-
Trondheim、ノルウェー、7006
- 募集
- St Olav University Hospital
-
コンタクト:
- Nina Nordskar, MD
-
コンタクト:
- Solveig Tingulstad, MD
-
-
Hordaland
-
Bergen、Hordaland、ノルウェー、5053
- 募集
- Women's hospital, Haukeland university hospital
-
コンタクト:
- Henrica MJ Werner, MD, PhD
- 電話番号:+4755974200
- メール:heaw@helse-bergen.no
-
コンタクト:
- Jone Trovik, prof MD PhD
- 電話番号:+4755974200
- メール:jone.trovik@uib.no
-
-
-
-
-
Lublin、ポーランド、20-081
- 募集
- Spsk No 1
-
コンタクト:
- Bartolomiej Barczynski, MD, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria part 1:
All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.
Exclusion Criteria part 1:
- Patients who do not have endometrial cancer
- Patients who will or cannot give informed consent (including language barriers)
- Patients <18 years of age
- Patients who will not get surgical treatment for their endometrial cancer
Inclusion criteria part 2:
- Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease.
- Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.
Exclusion criteria part 2:
- Patients not suffering from endometrial or epithelial ovarian cancer
- Patients <18 years of age
- Patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre
- Patients who cannot or do not want to give informed consent (including language barriers)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:phase 4 implementation study
The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm.
These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding.
Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
|
Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR). Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy. Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure. Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up. |
|
実験的:phase 2b biomarker study
For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
|
A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start. During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
number of recurrences after primary treatment
時間枠:5 year after diagnosis
|
The percentage of lymphadenectomy can be reduced safely and significantly, from 70% (MoMaTEC1 study results) to 30% in the MoMaTEC2 study through a better risk stratification of patients, especially better identification of low risk patients.
Additionally The percentage of patients who need to be subjected to adjuvant (chemo) therapy can be reduced similarly from 20 to 10%, based on the same, optimised risk stratification and better identification of low risk patients.
Patients will be rigorously followed during 5 years to detect any unexpected increase in the percentage of patients suffering a recurrence compared to the historical MoMaTEC1 cohort.
|
5 year after diagnosis
|
|
stathmin levels
時間枠:duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
|
stathmin level will be measured in metastatic tissue and related to response to treatment using Response Evaluation Criteria In Solid Tumors (RECIST) criteria
|
duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality of life measurements
時間枠:5 years post treatment
|
Quality of life will be measured through validated questionnaires (EORTC QLQ-C30 and EORTC QLQ-EN24).
|
5 years post treatment
|
|
correlation of stathmin llevels in tumor, urine and blood
時間枠:duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
|
stathmin tumor levels, urine levels and blood levels will be correlated.
|
duration of complete or partial treatment response in metastatic setting (expected duration less than one year)
|
協力者と研究者
捜査官
- 主任研究者:Henrica MJ Werner, MD PhD MRCOG、Haukeland University Hospital
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。